Search Results

Caliway Biopharmaceuticals (Caliway) today announced the topline results of the CBL-0201EFP Phase 2 study, which met all the primary and secondary efficacy endpoints in the ITT (Intent-to-treat) and PP (per-protocol) analysis population, demonstrating CBL-514’s statistically and clinically significant efficacy in improving cellulite severity with favorable safety and tolerance profiles.

Caliway Biopharmaceuticals announces that Australian Bellberry HREC has approved Caliway’s application to initiate CBL-514’s Pivotal Phase 3 study for subcutaneous fat reduction.

Caliway Biopharmaceuticals announced that the United States Food and Drug Administration has accepted the CBL-514 Investigational New Drug application of CBL-0202 DD Phase 2 Study to treat Dercum’s Disease.

ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and Systemic Lupus Erythematosus.

Oncocross , a Seoul-based AI drug discovery and development biotech, announced the completion of phase 1 global clinical trial of OC514, a treatment targeting sarcopenia and other rare muscular diseases.